Gyre Therapeutics (GYRE) Common Equity (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Common Equity data on file, last reported at $101.3 million in Q1 2026.

• Quarterly Common Equity fell 2.87% year-over-year to $101.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.3 million (down 2.87% YoY) and the FY2025 annual result came in at $142.3 million, up 44.59% from the prior year.
• Common Equity fell to $101.3 million in Q1 2026 per GYRE's latest filing, from $142.3 million in the prior quarter.
• Across five years, Common Equity topped out at $142.3 million in Q4 2025 and bottomed at $13.9 million in Q4 2023.
• The 5-year median for Common Equity is $88.8 million (2024), against an average of $83.5 million.
• The widest annual swing landed in 2023, when Common Equity slumped 80.68%; it then soared 605.44% in 2024.
• Tracing GYRE's Common Equity over 5 years: stood at $72.2 million in 2022, then tumbled by 80.68% to $13.9 million in 2023, then soared by 605.44% to $98.4 million in 2024, then jumped by 44.59% to $142.3 million in 2025, then slipped by 28.8% to $101.3 million in 2026.
• Per Business Quant, the three latest GYRE Common Equity figures stand at $101.3 million (Q1 2026), $142.3 million (Q4 2025), and $101.9 million (Q3 2025).

Peer Comparison